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Abstract. The T lymphocytes play an important role in prevention and recovery from viral infections. To char
acterize T lymphocyte responses to Japanese encephalitis (JE) virus infections, we analyzed JE virus-specific T
lymphocytes in peripheral blood mononuclear cells (PBMC) obtained from seven JE patients and 10 vaccinÃ©eswho
had received a formalin-inactivated, purified JE virus vaccine (Biken vaccine). These PBMC were examined for
proliferative responses against live JE virus, a glutaraldehyde-fixed lysate of cells infected with JE virus, and extra
cellular particles (EPs; subviral membrane vesicles released from cells infected with recombinant vaccinia viruses
encoding the JE virus premembrane and envelope proteins). Japanese encephalitis virus-specific T cell proliferation
was demonstrated with PBMC from both patients and vaccinÃ©esafter stimulation with infectious JE virus or the
lysate of JE virus-infected cells. Proliferating PBMC included CD4* T lymphocytes and CD8+ T lymphocytes in
responses to either form of JE viral antigens. Responses to EPs were observed only with PBMC from some American
vaccinÃ©eswhose PBMC also responded to the virus and lysate. These results indicate that JE virus infection and
immunization with an inactivated JE vaccine induce JE virus-specific CD4+ and CD8+ T memory lymphocytes that
can be induced to proliferate by infectious JE virus and noninfectious JE antigens.
Japanese encephalitis (JE) virus is a member of the Fla-
viviridue and causes human central nervous system disease.
Infections with JE virus are a significant cause of mortality
and morbidity in many areas of the world, especially in
Southeast Asia. Clinically overt JE infection causes fever,
headache, and impaired consciousness that results in death
in 5â€”20%of patients and in permanent neurologic impair
ment for many survivors.1-2 Infection with JE virus stimu
lates a strong humoral immune response: the detection of
immunoglobulin M (IgM) to JE virus or a significant in
crease in the titer of total antibody to JE virus is the labo
ratory criterion most often used for diagnosis of infection.
Although humoral immunity to JE virus has been extensive
ly studied in humans, cellular immunity has not.
Cellular immunity against infection with flaviviruses has
been studied using dengue.3 9 Murray Valley encephalitis,7-10
Kunjin,"~" and West Nile viruses.6" Reports on JE virus
using a mouse model revealed the presence of T suppressor
cells,14-'6 T helper cells,6 and B memory lymphocytes.17
However, there have been no reports of human T lymphocyte
responses to JE vaccination or infection.
Currently, the only JE vaccine approved for humans is a
formalin-inactivated virion preparation purified from JE vi
rus-infected mouse brains.1* Although this inactivated vac
cine has been demonstrated to be safe and effective,19 it is
expensive and has been occasionally associated with serious
adverse reactions.2" Recombinant poxviruses encoding the
premembrane (prM) and envelope (E) genes of JE virus have
been developed as a candidate second generation JE vaccine
to address the limitations of existing products.21 24The re-
combinant poxviruses elicited high levels of protective an
tibodies to JE virus in mice. The antibody responses of these
recombinant poxviruses correlated with their ability to in
duce the synthesis of extracellular particles (EPs) in tissue
culture cells. Furthermore, these EPs, which are virus-like
membrane vesicles containing prM, membrane (M). and E
proteins, are immunogenic and protective in mice,24-25and
could be considered for use as a subunit vaccine. To increase
their safety, our second generation JE vaccine candidates
were based on a highly attenuated vaccinia virus strain23 or
a canarypox strain.24
Effective evaluation of these vaccine candidates in hu
mans will require information on human T cell responses
against JE virus. In this paper we analyze JE virus-specific
T lymphocytes in peripheral blood mononuclear cells
(PBMC) from patients recovering from JE and vaccinÃ©es
who had received the commercially available inactivated
vaccine. The PBMC from the JE-immune donors prolifer
ated in vitro after stimulation with JE viral antigens, and the
proliferating cells included CD4* and CDS* T lymphocytes.
The T cells from some vaccinÃ©esalso responded to the EPs
that contained prM/M and E proteins. This report presents
the first information on JE virus-specific human T lympho
cytes.
MATERIALS AND METHODS
Human PBMC. The peripheral blood specimens were ob
tained from three different groups. The first group consisted
of seven adult American vaccinÃ©es(designated VU1 to
VU7) who had been immunized three or more times with
the formalin-inactivated JE vaccine (Biken vaccine)18 within
the past five years prior to the time of the study and who
resided in the United States, where JE virus is absent. The
second group consisted of three adult Japanese vaccinÃ©es
(designated VJ1 to VJ3) who had been vaccinated during
their childhood, had been given booster vaccinations within
the previous five years, and had resided in no other area
endemic for JE except Japan. One Japanese vaccinÃ©e(VJ1)
provided two specimens: the first (VJ1-1) was a baseline
sample, and the second (VJI-2) was collected one week after
a booster vaccination. The third group consisted of seven
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Thai patients (designated PT1 to PT7) who survived an ep
isode of JE defined by the presence of fever, impaired con
sciousness, and detection of IgM antibodies to JE virus in
the acute cerebrospinal fluid.26-27Their blood samples were
collected from one to seven months after the onset of the
disease. The control PBMC specimens were collected from
two cord blood samples (designated CB1 and CB2) supplied
by the University of Massachusetts Medical Center. The
PBMC were separated by Ficoll-Hypaque density gradient
centrifugation as previously described,4 resuspended at a
concentration of 1 X lOVml in RPMI 1640 medium con
taining 10% fetal bovine serum and 10% dimethylsulfoxide,
and cryopreserved in liquid nitrogen until use.
Viruses. The Nakayama strain of JE virus28was prepared
in an Aedes albopictus cell line (C6/36),29 which was ob
tained from the American Type Culture Collection (Rock-
ville, MD). A recombinant vaccinia virus encoding the prM
and E genes of the Nakayama strain of JE virus, vP829,22
and its parent virus, vP410,2' have been previously de
scribed.
Viral antigens. Live virus, fixed lysate of cells infected
with JE virus and purified EPs were used as viral antigens
in PBMC proliferation assays. Culture fluid of C6/36 cells
infected with JE virus at a multiplicity of infection (MOI)
of five and incubated at 28Â°Cfor 48 hr was used as the live
virus antigen (virus titer of approximately 2 X 10s plaque-
forming units/ml). The fixed cell lysate was prepared from
cells infected with JE virus essentially as described.4 Briefly,
Vero cells were infected with JE virus at an MOI of five,
incubated at 37Â°Cfor 24 hr, fixed in 0.025% glutaraldehyde,
sonicated, and clarified. The EPs were purified from culture
fluid of HeLa cells infected with vP829 as described.25 The
amounts of the JE virus E protein contained in the fixed cell
lysate and the EP antigens were 4 u.g/ml and 30 |JLg/ml,re
spectively, as estimated by Coomassie blue and immuno-
chemical staining. Control antigens for the live virus and
infected cell lysate consisted of uninfected C6/36 cell culture
fluid and uninfected Vero cell lysate. Control preparations
for the EP antigen were prepared from the culture fluid of
cells infected with vP410 by the same procedure used to
purify the EPs.
Radioimmunoprecipitation (RIP). Serum or plasma
specimens obtained from PBMC donors were tested for their
ability to immunoprecipitate "S-labeled viral proteins har
vested from the lysate of JE virus-infected cells as previ
ously described.21
Proliferation assay of PBMC. Proliferative responses of
PBMC were measured as previously described.4 The PBMC
(2 X IO5) were cultured with different dilutions of each of
the viral and control antigens in 0.2 ml of AIM V medium
(GIBCO BRL, Gaithersburg, MD) containing 10% human
AB serum (Hazleton Research Products, Inc., Lenexa, KS)
in 96-well V-bottom microplates (Costar, Cambridge, MA)
at 37Â°C.Based on the results of previous experiments, the
cell lysate was used at 1:20, 1:100, and 1:500 dilutions, live
virus was used at 1:4, 1:8, and 1:16 dilutions, and EP was
used at 1:10, 1:50, and 1:250 dilutions. Six days after ad
dition of antigen, cells were pulsed with 1 u,Ci of tritiated
(3H) thymidine for 18 hr before being harvested using a mul-
tiharvester (Titertek, Skatron Inc., Sterling, VA), and 3H-
thymidine incorporation was determined by liquid scintilla
tion counting (1205 Betaplate; Pharmacia, Wallac Oy, Fin
land). To improve the specific proliferative responses of
PBMC, T cell growth factor (TCGF; T-stim Culture Supple
ment; Collaborative Biomedicai Products, Bedford, MA)
was added to the PBMC from Thai patients, which had a
lower degree of viability at a final concentration of 1% or
10% six days after antigen addition except for those of PT2.
Stimulation indices were calculated by the standard formula:
count per minute (cpm) induced by JE antigen divided by
cpm induced by control antigen at the same dilution. The
criteria to determine positive responses were 1) a stimulation
index equal to or greater than 2.7 and 2) a total cpm obtained
with viral antigens greater than 500. A stimulation index
equal to or greater than 2.7 was considered as a positive
proliferation response, since the maximum value of the stim
ulation index of cord blood lymphocytes (for each concen
tration of antigens) plus 1.96 times the standard error of the
mean was 2.68.
Phenotypic analysis. The T lymphocyte depletion test
was performed using anti-CD4 and anti-CD8 monoclonal
antibodies (OKT4 and OKT8; Ortho Diagnostic Systems,
Inc., Raritan, NJ) as described.9 Briefly, approximately 1 x
IO6 PBMC stimulated with the lysate at a 1:20 dilution or
the virus at a 1:4 dilution were incubated with antibody at
a 1:11 dilution at 4Â°Cfor 30 min, treated with rabbit com
plement (Cedarlane Laboratories, Hornby, Ontario, Canada)
at a 1:5 dilution at 37Â°Cfor 1 hr, and then used in prolif
eration assays. The incorporation of 3H-thymidine was com
pared with that obtained with cells treated with mouse IgG
and complement. The percentage of the cells surviving after
depletion treatment (as shown by staining with the mono
clonal antibody used for depletion) had been demonstrated
to be less than 3% in previous experiments.
RESULTS
Antibody status. Figure 1 shows the RIP results of serum
or plasma specimens obtained from patients and vaccinÃ©es.
All the patients showed strong reactions to the E protein of
JE virus, and eight of 10 vaccinÃ©eshad detectable antibody
against the E protein. The specific reaction of one Japanese
vaccinÃ©e(VJ1-1) against E protein was not detectable on this
autoradiograph, but the specimen taken from the same in
dividual one week after vaccination (VJ1-2) showed a faint
band, as did VU4. The specimens from VU2 and VJ2 did
not show any detectable reactions against the E protein.
Patients had antibodies against nonstructural protein 1
(NS1) and NS3 of JE virus, but American vaccinÃ©esdid not
have antibodies against these nonstructural proteins. This
difference was anticipated since nonstructural proteins of JE
virus are excluded from the vaccine during its purification.
One of three Japanese vaccinÃ©es(VJ3) had low levels of
anti-NSl and anti-NS3 antibodies that were only visible with
longer exposure of the gel used to produce the autoradio-
graphs shown in Figure 1.
Proliferative responses of PBMC. The results of the pro
liferation assays of PBMC obtained from seven American
vaccinÃ©esand two cord blood samples are shown in Table
1. Positive responses against viral antigens were observed in
three vaccinÃ©es(VU1, VU3, and VU6), and the PBMC of
these three donors responded to all three antigen prepara-
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FIGUREI. Japanese encephalitis (JE) virusâ€”specific reactivity of sera or plasma obtained from American vaccinÃ©es(VU 1 to VU7), Japanese
vaccinÃ©es(VJl-1 to VJ3), and Thai patients (PT1 to PT7). These specimens were tested for their ability to immunoprecipitate radiolabeled
proteins harvested from JE virus-infected cells. The positions of JE virus proteins are shown on the left side of the autoradiograph. E =
envelope protein; NS1 and NS3 = nonstructural proteins; NSI' = a higher molecular weight form of NSI produced by alternative processing
of the sequences encoded by the NS2A region of the JE virus genome.30
lions: JE virus-infected cell lysate, live virus, and ER The
antigen dose that provided the maximum stimulation index
varied in different donors. Proliferation assays of PBMC
from three Japanese vaccinÃ©esshowed that PBMC of two
donors (VJ1-2 and VJ3) responded to the lysate and PBMC
of the donor VJ3 also responded to the virus (Table 2); how
ever, none of these three Japanese vaccinÃ©esshowed re
sponses to EP.
Proliferative responses of PBMC from Thai JE patients
are shown in Table 3. Since recovery of these PBMC sam
ples from cryopreservation was lower than with other PBMC
samples, TCGF was added to the PBMC culture at a final
concentration of 10% or 1% on day 6 to amplify the re
sponse in all assays except for those of PT2. Six of seven
patients showed responses to the lysate antigens, and five
patients showed responses to the live virus. The PBMC of
four patients (PT1, PT2, PT3, and PT5) also responded to
the lysate and JE virus without addition of TCGF. No pa
tients showed responses against the EP.
Phenotypic analysis of cells responding to antigens. To
characterize the proliferating cells, we depleted specific T
lymphocyte populations from the PBMC using monoclonal
antibodies and complement before 'H-thymidine incorpora
tion (Table 4). Cell depletion tests indicate that T lympho-
TABLE1
Proliferative responses of peripheral blood mononuclear cells from seven American vaccinÃ©es(VH) and two cord blood (CB) samples*
Stimulation index after stimulation with antigens
AntigenLysateVirusEPDilution1:201:1001:5001:41:81:161:101:501:250VUI3.9(2,274)9.9(5,710)4.5(3,141)2.3(18,631)3.8(16,578)0.8(5,105)3.2(12,237)1.4(12,890)2.3(9,813)VU21.0(456)1.8(528)0.9(246)0.9(3,380)0.9(1,283)0.9(624)0.4(156)0.4(255)0.6(253)VU31.4(369)2.5(701)2.7(1,038)3.1(9,287)1.8(7,098)4.3(5,669)2.2(600)4.9(1,908)2.9(1.138)VU41.4(803)2.2(834)0.7(406)1.3(6,130)1.3(3,098)0.7(1,877)1.1(301)0.6(462)0.7(316)vus1.2(168)1.2(116)1.0(95)1.6(364)0.5(123)1.0(89)0.2(84)1.1(114)0.8(82)VU61.3(187)9.9(1,921)16.2(2,323)15.0(8,070)5.3(4,457)3.5(1,645)11.5(2,328)3.8(721)5.4(954)VU71.7(1,060)1.7(815)1.8(1,436)1.5(10,598)1.1(5,661)1.9(6,597)0.7(454)1.4(952)0.9(982)C'B!0.9(
1.464)2.2(1,689)0.7(737)1.5(10,919)1.3(5,410)0.8(3,799)0.8(469)1.6(
1,306)0.8(709)CB20.9(1,493)2.0(2,853)0.7(1,273)0.8(7,532)0.7(5,637)0.6(2,346)0.8(423)1.3(1,787)1.1(1,731)
* Underlined values indicale significan! levels of proliferation. Values in parentheses are counts per minute. The data represent the averages of three wells. EP = extracellular particle.
JE VIRUS-SPECIFIC RESPONSES OF HUMAN T LYMPHOCYTES 281
TABLE2
Proliferative responses of peripheral blood mononuclear cells from
three Japanese vaccinÃ©es*
AntigenLysateVirusDilution1:201:1001:5001:41:81:16VJM0.6(175)0.9(135)1.1(149)0.3(219)0.9(145)1.0(135)Minili!
itVJ1
-20.4(1,548)2.8(8.241)1.8(6,902)1.8(24,533)0.6(8,908)1.1(7,119)on
indexVJ20.9(1,652)1.3(1,441)1.1(985)1.1(6,586)0.7(3,908)0.4(1,460)VJ33.7(3,960)2.2(2,190)1.4(724)1.7(8,399)1.9(4,275)3.2(3,965)
* Underlined values indicate significant levels of proliferation. Values in parentheses are
counts per minute. The data represent the averages of three wells. One individuai (VJ1)
provided two specimens.
cyte populations in PBMC that proliferated in responses to
the lysate and live virus included both CD4* T lymphocytes
and CDS* T lymphocytes in patients and vaccinÃ©es.The
percent decrease in stimulation by lysate after treatment with
anti-CD4 and complement was almost twice as great as that
after treatment with anti-CD8 and complement, indicating
that JE virus-specific CD4+ lymphocytes were more preva
lent (Table 4). The relative percent decreases achieved by
treatments with anti-CD4 or anti-CD8 and complement were
similar after stimulation with JE virus (Table 4).
DISCUSSION
This report describes the detection in vaccinÃ©esand re
covered patients of antibodies to both structural and non-
structural proteins of JE virus and JE virus-specific T mem
ory lymphocytes. The results are summarized in Table 5.
Our preliminary characterization of T lymphocyte prolifer
ative responses establishes another outcome measure with
which to evaluate the possible effectiveness of a candidate
second generation vaccine. The 92% efficacy of the first gen-
TABLE4
Effect of monoclonal antibodies and complement on the prolifera
tion of peripheral blood mononuclearcells responding to Japanese
encephalitis viral antigens*
'H-thymidine incorporation (counts per minute)
Treated with complement and
monoclonal antibody to
AntigenLysate
t
Virus*DonorPT5
VJ3
VJ3CD43,618(50.8%)
3,882 (44.7%)
1,349(63.8%)CDS5,324
(27.5%)
5,548 (21.0%)
2,0 4 (45.2%)Control
IgG7,348
7,019
3.730
* Values in parentheses are the percent reduction.
t 1:20 dilution.
Ã•1:4 dilution.
eration vaccine was demonstrated in a field trial in Thailand;
19therefore, a placebo-controlled trial of any new JE vaccine
would be unethical. Evidence of vaccine efficacy will be
based on protection studies in animals and on surrogate re
sponses of volunteers to vaccination. The ability of vaccine
to elicit neutralizing antibody is one candidate surrogate
marker. The ability of vaccine to elicit T cell responses is
also proposed as a new candidate marker. Specifically. T cell
proliferation responses would be advantageous to evaluate
recipients of live recombinant vaccine candidates, since in
general, cytotoxic T lymphocytes can be induced by infec
tion with live viruses in contrast to immuni/.ation with pro
teins or peptides; therefore, T lymphocyte proliferative re
sponsiveness does not always correlate with antibody.
The presence of antibodies to nonstructural proteins of JE
virus distinguished individuals infected with JE virus from
those immunized with an inactivated whole virion vaccine.
All seven patients recovering from the disease had antibod
ies to NS1 and NS3: in contrast, none of seven American
vaccinÃ©eshad those antibodies. These findings indicate that
during infection with JE virus, the immune system, including
T lymphocytes, encounters both structural and nonstructural
virus protein antigens, but that during vaccination with in
activated vaccine, T lymphocytes encounter only structural
virus protein antigens. Therefore, it is likely that the single
Japanese vaccinÃ©e(VJ3) who had anti-NSl and anti-NS3
TABLE3
Proliferative responses of peripheral blood mononuclear cells (PBMC) from seven Thai patients with Japanese encephalitis*
Stimulation index after stimulation with antigens
AntigenLysatetVirus*%TCGF10101010ITI3.5(14,262)4.6(7,367)7.1(9,687)4.4(3,301)7.5(3,972)4.0(3,479)PT29.2(2,252)5.4(1,009)3.0(533)4.0(2,291)2.4(1,455)3.3(738)PT312.0(35,460)12.1(31,654)9.5(19,885)4.1(25,733)4.1(26,800)6.0(14,476)PT45.0(2,139)1.4(564)1.3(602)1.0(1,119)0.8(203)1.0(156)PT56.7(29,650)2.3(13,348)3.0(10,291)4.0(27,501)2.1(6,772)4.0(4,860)PT62.1(3,632)3.5(5,072)0.7(1,126)0.9(10,125)4.2(9,878)0.8(1,245)PT71.9(4,564)1.2(2,794)1.1(1,558)0.7(903)0.5(1,937)0.5(249)
* Underlined values indicale significant levels of proliferation. Values in parentheses are counts per minute. The data represent the averages of three wells. T cell growth factor (TCGF) was
not used for assay of PBMC from PT2. Dala indicate responses against the lysate at dilutions of 1:20 (top line), 1:100 (middle line), and 1:500 (bottom line) and responses against virus at
dilutions of 1:4 (top line), 1:8 (middle line), and 1:16 (bottom line).
t 1:20 dilution except for PT2.
$1:16 dilution except for PT2.
282 KONISHI AND OTHERS
TABLE5
Summary of proliferative responses against Japanese encephalitis
virus antigens*
Antibody to
Donor
E
protein
NSI/NS3
proteins
T cell response to
Lysale Virus EP
American vaccinÃ©es
VUl +
VU2
VU3 +
VU4 +
VU5 +
VU6 +
VU7 +
Japanese vaccinÃ©es
VJl +
VJ2
VJ3 +
Patients
PT1 +
PT2 +
PT3 +
PT4 +
PT5 +
PT6 +
PT7 +
* E = envelope; NS = nonstructural; EP = extracellular panicle; + = positive response;
- = negative response. Results in parentheses were obtained in the presence of T cell
growth factor.
antibodies was naturally and asymptomatically infected with
JE virus in an endemic area (Japan). The presence of anti
bodies to nonstructural proteins in a vaccinÃ©ewith detectable
levels of neutralizing antibody is consistent with our previ
ous experiments in mice, which showed that animals with
high titers of neutralizing antibody that were protected
against lethal challenge produced antibodies to nonstructural
proteins.22
Japanese encephalitis virus-specific T lymphocytes were
detected in donors infected with JE virus or immunized with
the inactivated JE vaccine. The presence of specific lympho
cytes was shown in proliferation assays using several dif
ferent antigens. It is of interest that the responses of PBMC
against EPs were observed with specimens from American
vaccinÃ©esbut not with specimens from donors who were
infected with JE virus and have antibody to nonstructural
proteins. Similarly, a Japanese vaccinÃ©ewho had antibodies
against nonstructural protein (VJ3) did not respond to EPs
(Table 5). The immunogens encountered by the vaccinÃ©es
were limited to the structural proteins of JE virus, while
those encountered by patients would have included both
structural and nonstructural proteins produced in vivo during
virus replication. Detection of T memory cells that respond
to structural protein in PBMC of the vaccinÃ©esis consistent
with immunization with noninfectious JE virus particles. We
also expected to find T memory lymphocytes specific for the
structural proteins of JE virus in PBMC of the patients, since
the structural proteins induced a strong antibody response in
these individuals. However, we did not detect any prolifer
ation of T lymphocytes in PBMC of JE patients after in vitro
stimulation with EPs. These results suggest that JE virus-
specific T cells in JE patients respond mainly to nonstruc
tural proteins or capsid (C) protein, and the levels of T mem
ory cells that respond to E and prM/M proteins are unde-
tectably low. On the other hand, the results may be second
ary to the concentration of EPs used as the stimulating an
tigens.
It is important to determine which proteins of JE virus are
recognized by T cells from vaccinÃ©esand infected individ
uals to help ensure induction of T cell immunity in vacci
nÃ©es,and to help determine differences in T cell responses
of patients during JE infection. Vaccinia expression systems
have been used extensively to determine specific viral anti
gens involved in immune recognition of many viruses, in
cluding flaviviruses, in mice." l3 However, our earlier at
tempts to determine specific antigens of JE virus in human
PBMC using vaccinia-based recombinants" failed because
of high responses of human PBMC against vaccinia antigens
contained in the cell preparations. However, using the puri
fied EPs, we were able to identify T cells with specific reac
tivity to prM/M and E.
It is generally accepted that in vivo proliferation of human
leukocyte antigen (HLA) class I-restricted, CDS* T lym
phocytes tend to be stimulated by antigen presenting cells
(APC) infected with live agents and HLA class II-restricted,
CD4* T lymphocytes tend to be stimulated by APC sensi
tized with noninfectious proteins. We detected the prolifer
ation of both CD4* and CD8+ T cells in PBMC from two
donors (PT5 and VJ3). These two donors had antibodies to
NS1 and NS3, indicating that they had been infected with
JE virus in the past. The presence of JE virus-specific CD4+
and CD8+ T memory cells in PBMC of PT5 and VJ3 is
consistent with a history of JE virus infections.
In conclusion, we have demonstrated JE virus-specific
proliferation of both CD4* and CDS* T lymphocytes in
PBMC from patients and some vaccinÃ©es.The PBMC from
some vaccinÃ©esdid not proliferate, which is consistent with
low levels of T memory cells induced by the commercially
available inactivated JE vaccine. It is important to determine
the functions of these CD4* and CD8+ T cells, e.g., cyto-
toxic functions and lymphokine production, and to define the
protein(s) and epitope(s) recognized by these T cells. High
levels of proliferation in vitro will make it possible for us
to further characterize JE virus-specific T lymphocytes. The
improved understanding of JE virusâ€”specificT lymphocytes
may have important implications for the treatment of JE in
fection and for the development of new vaccines that are
safe and effective.
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